5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cells

被引:44
作者
Yao, Yongshan [1 ]
Chen, Shenghan [2 ]
Zhou, Xin [1 ]
Xie, Li [1 ]
Chen, Aijun [1 ]
机构
[1] China Three Gorges Univ, Dept Gen Surg 3, Coll Clin Med Sci 1, Yichang 443003, Hubei, Peoples R China
[2] China Three Gorges Univ, Dept Electrocardiog, Coll Clin Med Sci 1, Yichang 443003, Hubei, Peoples R China
关键词
5-FU; ixabepilone; luminal androgen receptor-type; triple-negative breast cancer; microRNA; PLUS CAPECITABINE; CHEMOTHERAPY; ANTHRACYCLINES; SIGNATURES; TAXANES; RELAPSE;
D O I
10.3892/ol.2013.1697
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study aimed to discover new potential mechanisms of chemotherapy with drugs used in the treatment of luminal androgen receptor (LAR)-type triple-negative breast cancer (TNBC). We examined the microRNA (miRNA) expression profiles of LAR-type TNBC in vitro, and explored the variation in miRNA expression profiles in cells when treated with the chemotherapy drugs capecitabine and ixabepilone. The present study revealed that the expression levels of the three antitumor miRNAs, miR-122a, miR-145 and miR-205, were significantly elevated in MDA-MB-453 LAR-type TNBC tumor cells treated with 5-fluorouracil together with ixabepilone. By contrast, carcinogenic miR-296 miRNA expression significantly declined, and levels of several other miRNAs such as miR-221, miR-210, miR-21 and miR-10b were also altered. The drugs may exert their effects through the regulation of miRNA expression levels, thereby providing a theoretical basis for clinical implementation of miRNA expression profiles as a diagnostic method for the early diagnosis, classification and prognosis of breast cancer.
引用
收藏
页码:541 / 547
页数:7
相关论文
共 43 条
[1]   MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer [J].
Andorfer, Cathy A. ;
Necela, Brian M. ;
Thompson, E. Aubrey ;
Perez, Edith A. .
TRENDS IN MOLECULAR MEDICINE, 2011, 17 (06) :313-319
[2]  
Brady-West DC, 2011, ASIAN PAC J CANCER P, V12, P2139
[3]   Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? [J].
Brenton, JD ;
Carey, LA ;
Ahmed, AA ;
Caldas, C .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (29) :7350-7360
[4]   MicroRNA signatures in human cancers [J].
Calin, George A. ;
Croce, Carlo M. .
NATURE REVIEWS CANCER, 2006, 6 (11) :857-866
[5]   MicroRNA-cancer connection: The beginning of a new tale [J].
Calin, George Adrian ;
Croce, Carlo Maria .
CANCER RESEARCH, 2006, 66 (15) :7390-7394
[6]   Characteristics of triple-negative breast cancer [J].
de Ruijter, Tim C. ;
Veeck, Jurgen ;
de Hoon, Joep P. J. ;
van Engeland, Manon ;
Tjan-Heijnen, Vivianne C. .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (02) :183-192
[7]   Ixabepilone: Clinical Role in Metastatic Breast Cancer [J].
Denduluri, Neelima ;
Swain, Sandra .
CLINICAL BREAST CANCER, 2011, 11 (03) :139-145
[8]   The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment [J].
Fornier, Monica ;
Fumoleau, Pierre .
BREAST JOURNAL, 2012, 18 (01) :41-51
[9]   Ixabepilone Plus Capecitabine for Breast Cancer Patients With an Early Metastatic Relapse After Adjuvant Chemotherapy: Two Clinical Trials [J].
Fornier, Monica .
CLINICAL BREAST CANCER, 2010, 10 (05) :352-358
[10]   Triple-Negative Breast Cancer [J].
Foulkes, William D. ;
Smith, Ian E. ;
Reis-Filho, Jorge S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20) :1938-1948